Back to search

National and Kapodistrian University of Athens

Κλινική και εργαστηριακή αξιολόγηση του ανοσοποιητικού συστήματος σε ασθενείς με καρκίνο του πνεύμονα που λαμβάνουν θεραπεία με αναστολείς των σημείων ελέγχου (checkpoint inhibitors)

Abstract

dc:description

Background: In-treatment monitoring of immunological and other peripheral blood parameters may reveal complementary biomarkers for immunotherapy in lung cancer. Objectives: To characterize the kinetics of peripheral blood immune parameters and investigate their association with clinical outcomes during immunotherapy. Methods: Patients with metastatic non-small cell lung cancer (NSCLC) receiving first-line pembrolizumab monotherapy were prospectively enrolled. Plasma samples were collected at predefined timepoints during the first year of treatment. Analyses included complete blood counts, biochemical parameters, cytokines, autoantibodies, soluble PD-L1 (sPD-L1), and pembrolizumab trough concentrations (Cmin). Clinical outcomes were assessed over a two-year follow-up period. Results: A total of 31 patients were enrolled over a two-year period. CRP, IL-6, IL-17α, and IL-8 levels decreased significantly during the first year of treatment (p < 0.01). White blood cells, neutrophils, CRP, and MIP-3α/CCL20 exhibited significant changes during the first three months of therapy (p < 0.01). Early kinetic analysis demonstrated a significant decrease in patients with high baseline LDH levels (p < 0.01), while significant increases in CXCL11 (p < 0.05), GM-CSF (p < 0.01), IL-4 (p < 0.05), and sPD-L1 (p < 0.05) were observed among patients with low baseline values. Pre-treatment autoantibody seropositivity was detected in 38.7% of patients, with limited dynamic changes during treatment (seroreversion 3.2%, emergence of new autoantibodies 30.8%, and seroconversion 9.7%). Pembrolizumab Cmin increased significantly during the first three months of treatment (p < 0.0001) and subsequently remained stable. Dynamic changes in immune parameters were not associated with clinical outcomes. In contrast, higher baseline levels of CRP, complement protein C4, and IL-6 were associated with poorer clinical outcomes. C4 emerged as an independent predictor of clinical benefit, while the integration of CRP, C4, and IL-6 into composite multiparametric scores improved prognostic performance. Conclusions: Monitoring selected peripheral blood biomarkers associated with systemic inflammation and an immune-resistant phenotype may provide clinically relevant prognostic information in patients receiving immunotherapy. The integration of these biomarkers into multiparametric models may improve the prediction of treatment outcomes and contribute to patient stratification. These findings require validation in larger prospective cohorts.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2026

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Trontzas, Ioannis
  • Τρόντζας, Ιωάννης

Subjects

dc:subject × 18

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/62139

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Trontzas, Ioannis; Τρόντζας, Ιωάννης. Κλινική και εργαστηριακή αξιολόγηση του ανοσοποιητικού συστήματος σε ασθενείς με καρκίνο του πνεύμονα που λαμβάνουν θεραπεία με αναστολείς των σημείων ελέγχου (checkpoint inhibitors). National and Kapodistrian University of Athens, 2026. http://hdl.handle.net/10442/hedi/62139